A professional institution
creating social values
and the future of the healthcare industry
Biohealth, the future growth engine

Major advanced countries such as the United States and Europe are making intensive investments at a governmental level towards research and development in biohealth. In Korea, the medical and pharmaceutical sectors have the most talented human resources in the nation, and the highest survival rates for major cancers in OECD prove its competence. Also, Korea has the world’s best information & communications infrastructure, hospital systems, and medical data in addition to sophisticated production management capabilities and technologies. Such infrastructure enables the rapid growth of the Korean biohealth industry. Korea is the world’s second largest biopharmaceutical manufacturing country, and exports of pharmaceuticals, medical devices, and cosmetics are also increasing. KHIDI will promote biohealth as one of the three new industries prioritized by the government together with system semiconductors and future cars, so that they can lead the future of Korea.
Korea Health Industry Development Institute will put forth its best effort to lead in the continuous growth of the Biohealth Industry.

**Mission & Vision**

**Mission**
To enhance public health by developing supportive infrastructure and ecosystem for the healthcare industry

**Vision**
To be a professional institution creating social values and the future of the healthcare industry

**Strategic Objectives**
- Development of supportive infrastructure for the healthcare industry
- Expansion of the healthcare industry’s ecosystem for new innovative growth
- Enhancement of the healthcare industry’s global competitiveness
- Establishment of a social value-based management system

**Strategic Tasks**

- **Professionalism**
  - Foster promising biohealth companies
  - Strengthen the global infrastructure of Korean healthcare
  - Enhance support for the healthcare industry to enter the global market

- **Convergent Innovation**
  - Raise global awareness on Korean healthcare
  - Reinforce management system for human resources based on professionalism
  - Conduct ethical management to meet public expectation

- **Social Responsibility**
  - Strengthen the global infrastructure of Korean healthcare
  - Enhance support for the healthcare industry to enter the global market

- **Communication & Engagement**
  - Foster promising biohealth companies
  - Strengthen the global infrastructure of Korean healthcare
  - Enhance support for the healthcare industry to enter the global market

- **Korea Health Industry Development Institute**
  - Develop supportive infrastructure for healthcare R&D
  - Establish the foundation for healthcare big data
  - Provide tailored support to boost the healthcare industry
  - Foster promising biohealth companies
  - Facilitate a new growth industry that leads 4th Industrial Revolution
  - Promote senior-friendly industry
  - Create social value and the future of the healthcare industry
KHIDI’s Qualifications

Team Player
Great communicators who create social values through teamwork and enhance organization’s reputation

Challenger
Great creatives who lead innovation of nation’s healthcare industry and explore global market

Professional
Great thinkers who possess professional knowledge and problem-solving capabilities in healthcare industry through constant self-improvement

Talent management

• Mentoring and training program to help new employees adjust
• Reinforcement of professionalism by assigning employees to tasks with consideration for each individual’s major, aptitude, and job objectives
• Identification of competent employees by operating a job posting program
• Fair promotions through an evaluation system based on abilities and performance
• Opportunities for overseas training to develop global competencies

A professional institution creating social values and the future of the healthcare industry
New change everyone dreams of begins with advanced technology. Change, which has value, brings about inspiration to many industries and technologies.

KHIDI quickly responds to changes in the healthcare business environment both at home and abroad by identifying innovative policy agendas and developing healthcare industry-related policies.

We are also making much effort in fostering the healthcare industry and supporting businesses to expand capacity of the biopharmaceutical industry and promote the medical device industry, while also expanding R&D activities focused on public health and supporting medical technology development through proactive public healthcare R&D. Moreover, we are strengthening the global competitiveness of the medical healthcare industry through intergovernmental cooperation aimed at vitalizing international healthcare in addition to creating new jobs in the process. KHIDI is fortifying domestic and overseas healthcare industries’ competitiveness with preemptive responses and innovative actions toward changes.

It is essential to establish healthcare industry infrastructure utilizing innovative technologies such as medical big data, digital healthcare, and smart hospital as well as uncover creative policy agendas to incorporate into policies.

We invest mainly in promising, next-generation technologies such as innovative new drugs, medical devices, and regenerative medicine and are focusing on supporting the development of medical technologies based on big data, AI, and other 4th Industrial Revolution technologies.

We provide consultation and help funding and investment attraction at the Biohealth Innovation Start-up Center to support businesses throughout the entire process, ensuring great healthcare technologies and ideas are commercialized.

Connect technology and people, add value to change

KHIDI supports medical institutions’ entry into overseas markets and promotes the use of medical facilities by foreign patients to facilitate the provision of safe and high-quality healthcare services to foreigners.

KHIDI supports medical institutions’ entry into overseas markets and promotes the use of medical facilities by foreign patients to facilitate the provision of safe and high-quality healthcare services to foreigners.
Policy Development for Healthcare Industry

Preemptive responses are vital to respond to the rapid environmental changes in the domestic and overseas healthcare industry. Therefore, it is essential to establish healthcare industry infrastructure utilizing innovative technologies such as medical big data, digital healthcare and smart hospital as well as uncover creative policy agendas to incorporate into policies.

With emergence of the 4th Industrial Revolution, the paradigm of healthcare industry is changing. Responding to the paradigm shift, it is necessary to lead healthcare industry into the next-generation. For this, we are exploring innovative agendas to support the established mid to long term policies set by the government.

Scope of activities

- Development of innovative agendas related to the healthcare industry
- Support for the development of mid/long-term policy establishment related to the healthcare industry
- Formation of social consensus toward policies supporting the healthcare industry
- Policy support for the development of talents in the healthcare industry

Preemptive responses are vital to respond to the rapid environmental changes in the domestic and overseas healthcare industry. Therefore, it is essential to establish healthcare industry infrastructure utilizing innovative technologies such as medical big data, digital healthcare and smart hospital as well as uncover creative policy agendas to incorporate into policies.

The scale of Korea’s healthcare industry

- **Pharmaceuticals**
  - 13th in the world
  - 17.9 billion USD
- **Medical devices**
  - 9th in the world
  - 6.5 billion USD
- **Cosmetics**
  - 8th in the world
  - 12.5 billion USD
- **Medical services**
  - 12th in the world
  - 123.9 billion USD

Analysis and policy development researches on the healthcare industry

We conduct researches to analyse healthcare industry and develop policies & strategies to enhance technical competitiveness, moreover, develop the way to improve social accessibility of health technologies.

Scope of activities

- Researches on the health industry policies
- Health industry analysis and future outlook
- Legislation and regulation reviews
- Domestic/international research collaboration

Utilizing healthcare data and establishing the basis for vitalization

Designated as a special institution for coupling and utilizing pseudonymous healthcare data, KHIDI supports invigoration of healthcare data and establishes a basis for biohealth data vitalization, which forms the background of precision medicine.

Scope of activities

- Operate a special institution for coupling of healthcare data
- Operate a platform connected with public institutions’ healthcare data
- Establish a basis for visualization of biohealth data
- Establish and operate a dispersed network of multi healthcare institutions
**Promote evidence-based digital healthcare**

Governance support for establishing research/evidence-based industry development policies such as regulations and systems to foster a Korean Digital New Deal within the domestic digital healthcare industry.

**Scope of activities**
- Survey and research related to digital healthcare such as domestic/foreign legal systems, policies, and industry trends
- Discover support projects for positive proof of digital healthcare products and services and support the development of evidence-based overall industry

**Support for validation of the health management service**

Support for vitalizing the market and building an innovation foundation of health management services for national public health and healthcare services enhancement.

**Scope of activities**
- Development of policies for vitalizing the market and creating demand for health management services
- Provision of customized statistics and trend analysis related to public health

**Policy Development and Support for future health**

KHIDI supports policy development for healthcare service innovation, data creation regarding medical institution management analysis for enhancement of healthcare service, and consulting to establish medical institution and strategy development.

**Scope of activities**
- Consult strategy development for healthcare service innovation
- Consult medical institution establishment and management
- Operate a business in financial accounting standards for medical institution
- Create data for medical institution management analysis

**Fostering and Supporting ‘Smart Hospital’**

KHIDI fosters Smart hospital, which is the core hospital for the realization of future smart healthcare. KHIDI also supports the development of a smart healthcare service model and organic connection & proliferation among medical institutions.

**Scope of activities**
- Analyze the trend of future health and develop policy agenda
- Provide consulting for setting strategy for smart hospital establishment
- Plan and operate smart hospital leading model development project
- Verification research on the effect of smart hospital and proliferate the research outcome

**Production and provision of healthcare statistics**

We are building a statistical foundation for new industries to support establishing policies and strategies related to the healthcare industry as a future growth engine. We produce high-quality statistics through nationally approved statistical data and provide statistical information in a timely manner through fact-finding surveys and trend analysis while predicting future trends in the industry.

**Export trends in the healthcare industry (Year 2000-2019)**

<table>
<thead>
<tr>
<th>Year</th>
<th>Pharmaceuticals</th>
<th>Medical Devices</th>
<th>cosmetics</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>$1 billion</td>
<td>$5 billion</td>
<td>$10 billion</td>
</tr>
<tr>
<td>2012</td>
<td>$1.1 billion</td>
<td>$5 billion</td>
<td>$10.9 billion</td>
</tr>
<tr>
<td>2016</td>
<td>$15.7 billion</td>
<td>$5 billion</td>
<td>$10.9 billion</td>
</tr>
<tr>
<td>2019</td>
<td>$15.7 billion</td>
<td>$5 billion</td>
<td>$10.9 billion</td>
</tr>
</tbody>
</table>

Source: KHIDI, reproduced, Korea Trade Statistics Promotion Institute
KHIDI is an institution specializing in the planning·evaluation·management of domestic R&D projects related to healthcare. We invest mainly in promising, next-generation technologies such as innovative new drugs, medical devices, and regenerative medicine and are focusing on supporting the development of medical technologies based on the 4th Industrial Revolution, such as big data and AI. We are also expanding R&D activities to areas to solve social issues such as contagious diseases, dementia, and mental health by reinforcing public investments.

Healthcare R&D Support

R&D project Planning
Survey analysis
Confirmation of implementation plan and announcement
Policy direction setting
Establishment of an evaluation plan
Project planning
Evaluation of proposal selection
Procurement of R&D budget
Signing of agreement
Performance Management
Inspection & management of progress
Settlement of research expenses
Technology transfer and commercialization
Survey on output utilization
Performance analysis
Project evaluation

Proposal Selection

Proposal Management

Performance Management

Support for the domestic production of materials·parts·equipment 6%
Biohealth industry innovation 36%
Hospital-based research ecosystem 16%
Reinforcement of public investment 42%
R&D investment of KHIDI (Unit: million USD)

Major achievements of healthcare R&D support

New drug development 30 cases
Medical device development 213 cases
International technology transfer 79 cases
Clinical trial 679 cases

Status of healthcare R&D support in the last 10 Years

R&D project Planning

Survey analysis
Confirmation of implementation plan and announcement
Policy direction setting
Establishment of an evaluation plan
Project planning
Evaluation of proposal selection
Procurement of R&D budget
Signing of agreement
Performance Management
Inspection & management of progress
Settlement of research expenses
Technology transfer and commercialization
Survey on output utilization
Performance analysis
Project evaluation

Proposal Selection

Proposal Management

Performance Management

Support for the domestic production of materials·parts·equipment 6%
Biohealth industry innovation 36%
Hospital-based research ecosystem 16%
Reinforcement of public investment 42%
R&D investment of KHIDI (Unit: million USD)

Major R&D projects in priority areas

24.7 million USD
- Reinforcement of support for the domestication of innovative new drugs, medical devices, and assistive devices

155.6 million USD
- Support for promising, next-generation technologies such as innovative new drugs, medical devices and regenerative medicine
- Development of medical technologies based on the 4th Industrial Revolution such as big data and AI

183 million USD
- Support for the domestic production of materials·parts·equipment
- Reinforcement of support for the domestication of vaccines, cosmetic ingredients, and assistive devices

68 million USD
- Development of hospitals into the innovation hubs of the research ecosystem
- Development of key talent who are capable of driving innovative growth

361.3 million USD
- Reinforcement of support for the domestication of innovative new drugs, medical devices, and assistive devices
- Support for promising, next-generation technologies such as innovative new drugs, medical devices and regenerative medicine
- Development of medical technologies based on the 4th Industrial Revolution such as big data and AI

R&D project Planning

Survey analysis
Confirmation of implementation plan and announcement
Policy direction setting
Establishment of an evaluation plan
Project planning
Evaluation of proposal selection
Procurement of R&D budget
Signing of agreement
Performance Management
Inspection & management of progress
Settlement of research expenses
Technology transfer and commercialization
Survey on output utilization
Performance analysis
Project evaluation

Proposal Selection

Proposal Management

Performance Management

Support for the domestic production of materials·parts·equipment 6%
Biohealth industry innovation 36%
Hospital-based research ecosystem 16%
Reinforcement of public investment 42%
R&D investment of KHIDI (Unit: million USD)

Major achievements of healthcare R&D support

New drug development 30 cases
Medical device development 213 cases
International technology transfer 79 cases
Clinical trial 679 cases

Status of healthcare R&D support in the last 10 Years

R&D project Planning

Survey analysis
Confirmation of implementation plan and announcement
Policy direction setting
Establishment of an evaluation plan
Project planning
Evaluation of proposal selection
Procurement of R&D budget
Signing of agreement
Performance Management
Inspection & management of progress
Settlement of research expenses
Technology transfer and commercialization
Survey on output utilization
Performance analysis
Project evaluation

Proposal Selection

Proposal Management

Performance Management

Support for the domestic production of materials·parts·equipment 6%
Biohealth industry innovation 36%
Hospital-based research ecosystem 16%
Reinforcement of public investment 42%
R&D investment of KHIDI (Unit: million USD)

Major R&D projects in priority areas

24.7 million USD
- Reinforcement of support for the domestication of innovative new drugs, medical devices, and assistive devices

155.6 million USD
- Support for promising, next-generation technologies such as innovative new drugs, medical devices and regenerative medicine
- Development of medical technologies based on the 4th Industrial Revolution such as big data and AI

183 million USD
- Support for the domestic production of materials·parts·equipment
- Reinforcement of support for the domestication of vaccines, cosmetic ingredients, and assistive devices

68 million USD
- Development of hospitals into the innovation hubs of the research ecosystem
- Development of key talent who are capable of driving innovative growth

361.3 million USD
- Reinforcement of support for the domestication of innovative new drugs, medical devices, and assistive devices
- Support for promising, next-generation technologies such as innovative new drugs, medical devices and regenerative medicine
- Development of medical technologies based on the 4th Industrial Revolution such as big data and AI

R&D project Planning

Survey analysis
Confirmation of implementation plan and announcement
Policy direction setting
Establishment of an evaluation plan
Project planning
Evaluation of proposal selection
Procurement of R&D budget
Signing of agreement
Performance Management
Inspection & management of progress
Settlement of research expenses
Technology transfer and commercialization
Survey on output utilization
Performance analysis
Project evaluation

Proposal Selection

Proposal Management

Performance Management

Support for the domestic production of materials·parts·equipment 6%
Biohealth industry innovation 36%
Hospital-based research ecosystem 16%
Reinforcement of public investment 42%
R&D investment of KHIDI (Unit: million USD)

Major achievements of healthcare R&D support

New drug development 30 cases
Medical device development 213 cases
International technology transfer 79 cases
Clinical trial 679 cases

Status of healthcare R&D support in the last 10 Years

R&D project Planning

Survey analysis
Confirmation of implementation plan and announcement
Policy direction setting
Establishment of an evaluation plan
Project planning
Evaluation of proposal selection
Procurement of R&D budget
Signing of agreement
Performance Management
Inspection & management of progress
Settlement of research expenses
Technology transfer and commercialization
Survey on output utilization
Performance analysis
Project evaluation

Proposal Selection

Proposal Management

Performance Management

Support for the domestic production of materials·parts·equipment 6%
Biohealth industry innovation 36%
Hospital-based research ecosystem 16%
Reinforcement of public investment 42%
R&D investment of KHIDI (Unit: million USD)

Major R&D projects in priority areas

24.7 million USD
- Reinforcement of support for the domestication of innovative new drugs, medical devices, and assistive devices

155.6 million USD
- Support for promising, next-generation technologies such as innovative new drugs, medical devices and regenerative medicine
- Development of medical technologies based on the 4th Industrial Revolution such as big data and AI

183 million USD
- Support for the domestic production of materials·parts·equipment
- Reinforcement of support for the domestication of vaccines, cosmetic ingredients, and assistive devices

68 million USD
- Development of hospitals into the innovation hubs of the research ecosystem
- Development of key talent who are capable of driving innovative growth

361.3 million USD
- Reinforcement of support for the domestication of innovative new drugs, medical devices, and assistive devices
- Support for promising, next-generation technologies such as innovative new drugs, medical devices and regenerative medicine
- Development of medical technologies based on the 4th Industrial Revolution such as big data and AI

R&D process
Major achievements

New drug development
- 16 new drugs, 4 immune vaccines, 6 biopharmaceuticals, 4 natural drugs
  - KANARB (new medication for high blood pressure): the first drug in Korea to achieve 100 million USD in exports
  - Development of SUPECT: the first Asian drug for leukemia treatment
  - Development of XCOPRI: a new innovative drug for the treatment of partial-onset seizure epilepsy in adults

Medical device development
- First in the world to develop L’DISQ navigable percutaneous disc decompensation device for treating herniated disc without surgery (grade 3 medical device)
- First in the world to develop NS-1, multiplex diagnostics for the detection of high-risk group viruses (grade 4 medical device)
- Development of NOVOSIS, injection type bone graft material complex (grade 4 medical device)
- There are four grades for medical devices. It is harder to develop and gain permits for higher grade due to higher risk.

International technology transfer
- 910 million USD* royalty (equal to 1.10 trillion KRW) for oral targeted anticancer drug between Hanmi Pharmaceutical - Genentech (US) (2016)
- 560 million USD royalty (equal to 670 billion KRW) for cancer immunotherapy between Gamnetech - I-Mab Biopharma (China) (2017)
- 1.26 billion USD royalty (equal to 1.50 trillion KRW) for lung cancer treatment drug between Juhan - Janssen (US) (2018)
- 330 million USD royalty (equal to 400 billion KRW) for an anti-epileptic drug between SK Biopharmaceuticals - Arvelle Therapeutics (Switzerland) (2019)
- 3.84 billion USD royalty (equal to 4,600 billion KRW) for source technology of hypodemic injection between Alteogen – overseas pharmaceutical company (2020)

Journals and patents
Journal and patent achievements (Unit : no. of cases)
- SCI(E) journals: 2,233 cases
- Patent application: 993 cases
- Patent registration: 616 cases

Clinical trials
Number of clinical trials (Year 2018)
- Domestic clinical trial: 393 cases
- Multistate clinical trial: 286 cases

International technology transfer cases
- 79 cases

Country ranking for clinical trials
- 2018: 1st

Seoul City ranking for clinical trials
- 2007: 19th
- 2018: 1st
Fostering Healthcare Industry and Supporting Business

We provide services from consultation, funding, and investment attraction at the Biohealth Innovation Start-up Center to support businesses throughout the entire process, ensuring great healthcare technologies and ideas are commercialized. Our goal is to support global business expansion by strengthening the capacity of Korea's pharmaceutical industry, fostering the medical device industry by implementing the Medical Device Industry Act, and facilitate the commercialization of innovative medical devices.

Achievements of healthcare industry promotion programs

- Total revenue of healthcare start-ups supported by KHIDI (Year 2016): 34.2 billion won
- Certified innovative pharmaceutical companies: 45 companies
- Total number of companies and amount of government funding (including R&D and program support, tax benefits, and price incentives) (Year 2018): 747.2 billion won
- Total revenue of Korea medical device manufacturers with governmental support based on user evaluation (Year 2018 to 2020, accumulated): 45 companies (45.2 billion won)

Support for transfer of biohealth technology and vitalization of start-ups

For successful commercialization of promising Korean biotechnologies, we operate a healthcare TLO and technology trade markets. Startups are also provided with office space at the Biohealth Innovation Start-up Center, consultation on patent, technology valuation, and assistance in prototype production, all of which can help their growth.

Support for Korea’s leap forward to become a global biopharmaceutical powerhouse

We have carried out development and support policies including the innovative pharmaceutical company certification system under the Pharmaceutical Industry Promotion Act in order to foster the growth of the domestic biopharmaceutical industry into a core industry that contributes to the national economy. We are at the forefront of creating the foundation for an industrial ecosystem that helps Korean companies’ global expansion and capacity building.

Scope of activities

Support for successful commercialization by discovering excellent technology and assisting technology transfer
Operation of BIO KOREA and other technology trade platforms
Provision of office space for business incubation and operation
Operation of support programs to boost growth of start-up companies

Achievements of healthcare industry promotion programs

- Total revenue of healthcare start-ups supported by KHIDI (Year 2016): 34.2 billion won
- Certified innovative pharmaceutical companies: 45 companies
- Total number of companies and amount of government funding (including R&D and program support, tax benefits, and price incentives) (Year 2018): 747.2 billion won
- Total revenue of Korea medical device manufacturers with governmental support based on user evaluation (Year 2018 to 2020, accumulated): 45 companies (45.2 billion won)
The healthcare industry is truly a field that is capable of continually increasing new start-ups* and employment**. It is most important to create a cyclic ecosystem where R&D achievements lead to start-ups, which in turn lead to job creation.

As part of an effort to boost start-ups and vitalize ecosystems, the Biohealth Innovation Start-up Center opened its doors in 2018. The Center has project managers dedicated to discovering promising ideas and technologies to provide life-cycle support from professional consultation to technology valuation, investment attraction, and setting-up of sales channels.

Support for the development of the medical device industry

We support the enactment and implementation of government policies including the Act on the Development of the Medical Device Industry and Support for Innovative Medical Devices. We are leading the effort of laying the foundation for an industrial ecosystem to help Korea’s medical device businesses to build competitiveness and enter into overseas markets.

** Number of people employed by surviving start-ups in the recent seven years (Year 2011-2017)

** Total number of people employed by surviving start-ups in the recent seven years (Year 2011-2017)

Support for the development of senior-friendly industries

In order to actively respond to population aging and to improve the quality of life of the elderly as well as to contribute to sound economic growth, we are promoting policies to foster and support senior-friendly industries under the Framework Act on Low Birth Rate in Aging Society and Senior-Friendly Industry Promotion Act.

Support for the development of the beauty & cosmetics industry

We are striving to enhance K-beauty brands’ competitiveness and promote exports by discovering policy tasks to foster the cosmetics industry’s leap forward as a ‘G3 cosmetic export country’, and by developing and expanding sales channels for domestic small and medium-sized cosmetics companies to enter overseas markets.

Support for the development of senior-friendly industries

The healthcare industry is truly a field that is capable of continually increasing new start-ups* and employment**. It is most important to create a cyclic ecosystem where R&D achievements lead to start-ups, which in turn lead to job creation.

** Number of people employed by surviving start-ups in the recent seven years (Year 2011-2017)

** Total number of people employed by surviving start-ups in the recent seven years (Year 2011-2017)

Support for the development of the beauty & cosmetics industry

We are striving to enhance K-beauty brands’ competitiveness and promote exports by discovering policy tasks to foster the cosmetics industry’s leap forward as a ‘G3 cosmetic export country’, and by developing and expanding sales channels for domestic small and medium-sized cosmetics companies to enter overseas markets.
KHIDI supports to protect rights and interests of foreign patients and promotes the convenience of medical use in Korea so that the patients can receive safe and high-quality medical and healthcare services. Through intergovernmental cooperation, KHIDI enhances the international competitiveness of nation’s healthcare industry and contributes to the industry a high added value with job creation.

Supporting Vitalization of Global Healthcare

Since 2009 when Korean medical institutions were officially allowed to accept foreign patients, the accumulated number of foreign patients who visited Korea amounted to 7.09 million, while annual figures of 2019 reached 1 million.

* KHIDI annually analyzes the statistics of foreign patients.

<table>
<thead>
<tr>
<th>Year</th>
<th>No. of foreign patients</th>
<th>No. of countries where foreign patients came from</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>1,076,813</td>
<td>199 countries</td>
</tr>
<tr>
<td>2018</td>
<td>816,691</td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>790,730</td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>650,411</td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>474,939</td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>344,407</td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>224,260</td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td>162,638</td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>39,737</td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td>162,638</td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td>7,09 million persons</td>
<td>199 countries</td>
</tr>
</tbody>
</table>
Creation of a convenient and safe healing environment for Korean medical services

- Satisfaction level of foreign patients who experienced Korean medicine (2018: 90.5 points • 2019: 91 points)
- Foreign patients showed a high level of satisfaction in a variety of areas such as “service”, “hospital convenience”, “accessibility”, “communication and respect towards patients”, “hospital accommodation”, “provision of information and training”, and “medical expenses” etc.
- Awarded ‘Health and Medical Tourism : Destination of Year’ for two consecutive years at the TMT Medical Travel Awards’ (2016, 2019)
- Ranked 1st place for two consecutive years in terms of awareness and preference amongst medical tourism destinations in the Foreign Awareness Survey on Korea Medical Wellness(Korea Tourism Organization), which started in 2018

We provide a convenient and safe healing environment for foreign patients who received treatment at Korean medical institutions.

Satisfaction level of foreign patients

90.5 points

2018

91 points

2019

Complimentary Medical Treatment via Medical Charity Program

26 countries

404 persons

We disseminate a value of international contributions by focusing on core competencies and resources of the public and private medical institutions to realize the core value of medical care through co-prosperity beyond competition in the global healthcare market.

Medical Charity Program

Implementation of ‘Medical Charity Program’ which invites foreign patients with lack of access to healthcare services and provides necessary treatment they are unable to receive elsewhere - 404 patients from 26 countries received complementary medical treatment via Korea Medical Charity Program from 2011 to 2019.

Medical KOREA ACADEMY

‘MEDICAL KOREA ACADEMY’ provides opportunities for outstanding foreign medical practitioners to get professional training from Korean medical institutions
- Observation Course (Medical Korea Academy-Global, Korea-Mongolia, Korea-Russia): completed by 703 persons from 32 countries
- Clinical Training Course (Middle-Eastern Physician & Dentist): completed by 161 persons from 4 countries (Saudi Arabia, Kuwait, Bahrain, Oman)
- Initiating the Online Training Program (MKA e-class) is available to prepare for the post-COVID era

Charity Program

Medical Observation

Medical Clinical

No. of trainees completed

Medical Charity Program (Year 2017-2019)

Korea-Mongolia

Korea-Russia

82 persons

173 persons

448 persons

703 persons completed

26 countries

404 persons

No. of trainees completed

Medical Charity Program (Year 2015-2019)

Korea-Mongolia

Korea-Russia

448 persons

173 persons

149 persons

161 persons completed

Global CSR and creation of shared values by Korean medical institutions

We disseminate a value of international contributions by focusing on core competencies and resources of the public and private medical institutions to realize the core value of medical care through co-prosperity beyond competition in the global healthcare market.
KHIDI Information

Major Events

BIO KOREA
As the largest international biohealth convention in Asia, it has been held annually since 2006, featuring conferences, business meetings, and exhibitions.

MEDICAL KOREA
It is an international conference held since 2010 to share the trends and prospects of the global healthcare and medical tourism industry.

History

February 1999
Korea Health Industry Development Institute (KHIDI) founded

January 2000
Designated as an institution for the management of R&D projects related to healthcare technology

January 2001
Designated as an institution specialized in technology trade and evaluation in the healthcare industry

February 2006
Hosted the 1st BIO KOREA

January 2008
Designated as Senior-friendly Industry Support Center

May 2008
Designated as an institution authorized to produce national statistics (Statistics Korea)

December 2009
Announced MEDICAL KOREA brand

November 2010
Moved to Cosing Health Technology Administrative Complex

June 2012
Started to provide support for graduate schools specialized in pharmaceutical industry, medical devices (September 2013), senior-friendly (September 2015)

June 2012
Started authorization program for innovative pharmaceutical companies

September 2010
Designated as supporting institution for overseas healthcare expansion and foreign patient attraction

March 2018
Opened Biohealth Innovation Start-up Center

September 2019
Launched Healthcare big data platform

February 2016
Opened MEDICAL KOREA Information Center

June 2016
Designated as supporting institution for overseas healthcare expansion and foreign patient attraction

March 2018
Opened Biohealth Innovation Start-up Center

September 2019
Launched Healthcare big data platform

May 2020
Operated a support center to alleviate problems faced by companies developing COVID-19 treatments/vaccines

October 2020
Designated as a special institution for coupling and utilizing of pseudonymous healthcare data

Awards

• Job of the Year (Year 2018-2020, Ministry of Employment and Labor)
• Korea Knowledge Award (Year 2019-2020, Ministry of the Interior and Safety)
• The MITF Medical Travel Award (Year 2019-2020, MITF)
• Porter Prize for Excellence in CSV (Year 2019, The Institute for Industrial Policy Studies)
• Korea Trusted Innovation Awards (Year 2020, Ministry of Trade, Industry and Energy)

KHIDI’s Support for the Industry

Senior-friendly Industries
MEDICAL KOREA
www.khidi.or.kr/medicalKorea

Health Technology R&D Portal
www.htdream.kr

KHISS Healthcare Industry Statistics
www.khiss.go.kr

BIO KOREA
www.biokorea.org

Biohealth Innovation Start-up Center
www.khidi.or.kr/bhisc

Visit Medical Korea
www.visitmedicalkorea.co.kr

Korea Overseas Hospital Expansion Service
www.khidi.or.kr/kohes

Medical Device Industry Information
www.khidi.or.kr/meddev

Pharmaceutical Industry Information Portal
www.khidi.or.kr/epharmakorea